<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:fff587ec-dfa6-4590-809a-e4fc7afc17c7"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="fb9348b0-aa2d-416b-a153-4a2961e56f3c"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-05-19T18:53:51Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:12b067a7-7785-4c1a-96ad-70eeefb432e4"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
							<contained>
                                <Binary>
                                	<id value="image0"/>
                                	<!-- example format -->
                                	<contentType value="image/png"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="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"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image0"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image1"/>
                                	<!-- example format -->
                                	<contentType value="image/jpg"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="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"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image1"/>
                        		</valueReference>
               </extension>
              
              
              <contained>
                          <Binary>
                            <id value="stylesheet0"/>
                            <!-- example format -->
                            <contentType value="stylesheet/css"/>
                            <!-- data is base 64 encoded, actual bytes of the image png file -->
                            <data value="<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	text-transform:uppercase;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1 Char\,Comment Text Char1 Char Char\,Comment Text Char2 Char";
	mso-style-link:"Comment Text Char\,Comment Text Char Char Char\,Comment Text Char Char Char Char Char\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char Char\,Comment Text Char2 Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,B Caption\,Bayer Caption\,Caption2\,IB Caption\,Medical Caption\,Table Caption";
	mso-style-link:"Caption Char\,B Caption Char\,Bayer Caption Char\,Caption2 Char\,IB Caption Char\,Medical Caption Char\,Table Caption Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Calibri Light",sans-serif;}
span.MsoFootnoteReference
	{vertical-align:super;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:107%;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin:0in;
	line-height:normal;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-link:"Title Char";
	margin:0in;
	line-height:normal;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-link:"Title Char";
	margin:0in;
	line-height:normal;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-link:"Title Char";
	margin:0in;
	line-height:normal;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#5A5A5A;
	letter-spacing:.75pt;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-indent:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:10.5pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:8.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:107%;
	font-size:8.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.8in;
	margin-bottom:8.0pt;
	margin-left:.8in;
	line-height:107%;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#4472C4;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Segoe UI",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:normal;
	font-size:10.5pt;
	font-family:Consolas;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-style:italic;}
kbd
	{font-family:"Courier New";}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
span.MsoPlaceholderText
	{color:gray;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin-top:10.0pt;
	margin-right:.6in;
	margin-bottom:8.0pt;
	margin-left:.6in;
	text-align:center;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#404040;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:.25in;
	margin-right:.6in;
	margin-bottom:.25in;
	margin-left:.6in;
	text-align:center;
	line-height:107%;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#4472C4;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	line-height:normal;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Comment Text Char Char Char\,Comment Text Char Char Char Char Char\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char Char\,Comment Text Char2 Char Char";
	mso-style-link:"Comment Text\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1 Char\,Comment Text Char1 Char Char\,Comment Text Char2 Char";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.documenttextoutlinenumbered, li.documenttextoutlinenumbered, div.documenttextoutlinenumbered
	{mso-style-name:"document text outline numbered";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.C-BodyText, li.C-BodyText, div.C-BodyText
	{mso-style-name:"C-Body Text";
	mso-style-link:"C-Body Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.C-BodyTextChar
	{mso-style-name:"C-Body Text Char";
	mso-style-link:"C-Body Text";
	font-family:"Times New Roman",serif;}
span.Mention1
	{mso-style-name:Mention1;
	color:#2B579A;
	background:#E6E6E6;}
p.C-Bullet, li.C-Bullet, div.C-Bullet
	{mso-style-name:C-Bullet;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-BulletIndented, li.C-BulletIndented, div.C-BulletIndented
	{mso-style-name:"C-Bullet Indented";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.tablefootnote, li.tablefootnote, div.tablefootnote
	{mso-style-name:"table footnote";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.CaptionChar
	{mso-style-name:"Caption Char\,B Caption Char\,Bayer Caption Char\,Caption2 Char\,IB Caption Char\,Medical Caption Char\,Table Caption Char";
	mso-style-link:"Caption\,B Caption\,Bayer Caption\,Caption2\,IB Caption\,Medical Caption\,Table Caption";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.C-Hyperlink
	{mso-style-name:C-Hyperlink;
	color:blue;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Arial",sans-serif;}
p.C-Heading1, li.C-Heading1, div.C-Heading1
	{mso-style-name:"C-Heading 1";
	mso-style-link:"C-Heading 1 Char";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Heading2, li.C-Heading2, div.C-Heading2
	{mso-style-name:"C-Heading 2";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading3, li.C-Heading3, div.C-Heading3
	{mso-style-name:"C-Heading 3";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading4, li.C-Heading4, div.C-Heading4
	{mso-style-name:"C-Heading 4";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading5, li.C-Heading5, div.C-Heading5
	{mso-style-name:"C-Heading 5";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading6, li.C-Heading6, div.C-Heading6
	{mso-style-name:"C-Heading 6";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.85in;
	text-indent:-.85in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-BodyTextIndent, li.C-BodyTextIndent, div.C-BodyTextIndent
	{mso-style-name:"C-Body Text Indent";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-TableHeader, li.C-TableHeader, div.C-TableHeader
	{mso-style-name:"C-Table Header";
	margin-top:1.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-TableText, li.C-TableText, div.C-TableText
	{mso-style-name:"C-Table Text";
	margin-top:1.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.C-TableFootnote, li.C-TableFootnote, div.C-TableFootnote
	{mso-style-name:"C-Table Footnote";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.1in;
	text-indent:-.1in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.C-TOCTitle, li.C-TOCTitle, div.C-TOCTitle
	{mso-style-name:"C-TOC Title";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	line-height:normal;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-CaptionContinued, li.C-CaptionContinued, div.C-CaptionContinued
	{mso-style-name:"C-Caption Continued";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-NumberedList, li.C-NumberedList, div.C-NumberedList
	{mso-style-name:"C-Numbered List";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-InstructionText, li.C-InstructionText, div.C-InstructionText
	{mso-style-name:"C-Instruction Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:red;
	display:none;}
p.C-Title, li.C-Title, div.C-Title
	{mso-style-name:C-Title;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	line-height:normal;
	font-size:18.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Header, li.C-Header, div.C-Header
	{mso-style-name:C-Header;
	margin:0in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-Footer, li.C-Footer, div.C-Footer
	{mso-style-name:C-Footer;
	margin:0in;
	text-align:right;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-Heading1non-numbered, li.C-Heading1non-numbered, div.C-Heading1non-numbered
	{mso-style-name:"C-Heading 1 \(non-numbered\)";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Heading2non-numbered, li.C-Heading2non-numbered, div.C-Heading2non-numbered
	{mso-style-name:"C-Heading 2 \(non-numbered\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading3non-numbered, li.C-Heading3non-numbered, div.C-Heading3non-numbered
	{mso-style-name:"C-Heading 3 \(non-numbered\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading4non-numbered, li.C-Heading4non-numbered, div.C-Heading4non-numbered
	{mso-style-name:"C-Heading 4 \(non-numbered\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading5non-numbered, li.C-Heading5non-numbered, div.C-Heading5non-numbered
	{mso-style-name:"C-Heading 5 \(non-numbered\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading6non-numbered, li.C-Heading6non-numbered, div.C-Heading6non-numbered
	{mso-style-name:"C-Heading 6 \(non-numbered\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading1nopagebreak, li.C-Heading1nopagebreak, div.C-Heading1nopagebreak
	{mso-style-name:"C-Heading 1 \(no page break\)";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Heading1nopagebreak0, li.C-Heading1nopagebreak0, div.C-Heading1nopagebreak0
	{mso-style-name:"C-Heading 1 \(no page break\,non-numbered\)";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-AlphabeticList, li.C-AlphabeticList, div.C-AlphabeticList
	{mso-style-name:"C-Alphabetic List";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-Appendix, li.C-Appendix, div.C-Appendix
	{mso-style-name:C-Appendix;
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:99.35pt;
	text-indent:-99.35pt;
	line-height:normal;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.C-TableCallout
	{mso-style-name:"C-Table Callout";
	font-family:"Times New Roman",serif;
	color:windowtext;
	position:relative;
	top:.5pt;
	letter-spacing:0pt;
	text-decoration:none none;
	vertical-align:super;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
p.C-AppendixNumbered, li.C-AppendixNumbered, div.C-AppendixNumbered
	{mso-style-name:"C-Appendix \(Numbered\)";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:99.35pt;
	text-indent:-99.35pt;
	line-height:normal;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Alphabetic, li.C-Alphabetic, div.C-Alphabetic
	{mso-style-name:C-Alphabetic;
	mso-style-link:"C-Alphabetic Char";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Footnote, li.C-Footnote, div.C-Footnote
	{mso-style-name:C-Footnote;
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.C-Heading1Char
	{mso-style-name:"C-Heading 1 Char";
	mso-style-link:"C-Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.C-AlphabeticChar
	{mso-style-name:"C-Alphabetic Char";
	mso-style-link:C-Alphabetic;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
span.normaltextrun
	{mso-style-name:normaltextrun;}
span.spellingerror
	{mso-style-name:spellingerror;}
p.DisclaimerAgency, li.DisclaimerAgency, div.DisclaimerAgency
	{mso-style-name:"Disclaimer \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:0in;
	line-height:7.5pt;
	font-size:6.5pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;
	layout-grid-mode:line;}
p.DoccategoryheadingAgency, li.DoccategoryheadingAgency, div.DoccategoryheadingAgency
	{mso-style-name:"Doc category heading \(Agency\)";
	margin-top:28.35pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:normal;
	page-break-after:avoid;
	border:none;
	padding:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:#003399;
	font-weight:bold;}
p.DocsubtitleAgency, li.DocsubtitleAgency, div.DocsubtitleAgency
	{mso-style-name:"Doc subtitle \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:32.0pt;
	margin-left:0in;
	line-height:18.0pt;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;}
p.DoctitleAgency, li.DoctitleAgency, div.DoctitleAgency
	{mso-style-name:"Doc title \(Agency\)";
	margin-top:.5in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:18.0pt;
	font-size:16.0pt;
	font-family:"Verdana",sans-serif;
	color:#003399;}
span.EndnotereferenceAgency
	{mso-style-name:"Endnote reference \(Agency\)";
	font-family:"Verdana",sans-serif;
	vertical-align:super;}
p.EndnotetextAgency, li.EndnotetextAgency, div.EndnotetextAgency
	{mso-style-name:"Endnote text \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:7.5pt;
	font-family:"Verdana",sans-serif;}
p.FigureAgency, li.FigureAgency, div.FigureAgency
	{mso-style-name:"Figure \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-align:center;
	line-height:107%;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.FigureheadingAgency, li.FigureheadingAgency, div.FigureheadingAgency
	{mso-style-name:"Figure heading \(Agency\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.FooterAgency, li.FooterAgency, div.FooterAgency
	{mso-style-name:"Footer \(Agency\)";
	mso-style-link:"Footer \(Agency\) Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
span.FooterAgencyCharChar
	{mso-style-name:"Footer \(Agency\) Char Char";
	mso-style-link:"Footer \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.FooterblueAgency, li.FooterblueAgency, div.FooterblueAgency
	{mso-style-name:"Footer blue \(Agency\)";
	mso-style-link:"Footer blue \(Agency\) Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:6.5pt;
	font-family:"Verdana",sans-serif;
	color:#003399;
	font-weight:bold;}
span.FooterblueAgencyCharChar
	{mso-style-name:"Footer blue \(Agency\) Char Char";
	mso-style-link:"Footer blue \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#003399;
	font-weight:bold;}
span.FootnotereferenceAgency
	{mso-style-name:"Footnote reference \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:windowtext;
	vertical-align:super;}
p.FootnotetextAgency, li.FootnotetextAgency, div.FootnotetextAgency
	{mso-style-name:"Footnote text \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:7.5pt;
	font-family:"Verdana",sans-serif;}
p.HeaderAgency, li.HeaderAgency, div.HeaderAgency
	{mso-style-name:"Header \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.Heading1Agency, li.Heading1Agency, div.Heading1Agency
	{mso-style-name:"Heading 1 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading2Agency, li.Heading2Agency, div.Heading2Agency
	{mso-style-name:"Heading 2 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading3Agency, li.Heading3Agency, div.Heading3Agency
	{mso-style-name:"Heading 3 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading4Agency, li.Heading4Agency, div.Heading4Agency
	{mso-style-name:"Heading 4 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading5Agency, li.Heading5Agency, div.Heading5Agency
	{mso-style-name:"Heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading6Agency, li.Heading6Agency, div.Heading6Agency
	{mso-style-name:"Heading 6 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading7Agency, li.Heading7Agency, div.Heading7Agency
	{mso-style-name:"Heading 7 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading8Agency, li.Heading8Agency, div.Heading8Agency
	{mso-style-name:"Heading 8 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading9Agency, li.Heading9Agency, div.Heading9Agency
	{mso-style-name:"Heading 9 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading1Agency, li.No-numheading1Agency, div.No-numheading1Agency
	{mso-style-name:"No-num heading 1 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.HeadingcentredAgency, li.HeadingcentredAgency, div.HeadingcentredAgency
	{mso-style-name:"Heading centred \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-align:center;
	line-height:107%;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading2Agency, li.No-numheading2Agency, div.No-numheading2Agency
	{mso-style-name:"No-num heading 2 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading4Agency, li.No-numheading4Agency, div.No-numheading4Agency
	{mso-style-name:"No-num heading 4 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.No-numheading5Agency, li.No-numheading5Agency, div.No-numheading5Agency
	{mso-style-name:"No-num heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading6Agency, li.No-numheading6Agency, div.No-numheading6Agency
	{mso-style-name:"No-num heading 6 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading7Agency, li.No-numheading7Agency, div.No-numheading7Agency
	{mso-style-name:"No-num heading 7 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading8Agency, li.No-numheading8Agency, div.No-numheading8Agency
	{mso-style-name:"No-num heading 8 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading9Agency, li.No-numheading9Agency, div.No-numheading9Agency
	{mso-style-name:"No-num heading 9 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-TOCheadingAgency, li.No-TOCheadingAgency, div.No-TOCheadingAgency
	{mso-style-name:"No-TOC heading \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.PagenumberAgency, li.PagenumberAgency, div.PagenumberAgency
	{mso-style-name:"Page number \(Agency\)";
	mso-style-link:"Page number \(Agency\) Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-align:right;
	line-height:107%;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
span.PagenumberAgencyCharChar
	{mso-style-name:"Page number \(Agency\) Char Char";
	mso-style-link:"Page number \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.RefAgency, li.RefAgency, div.RefAgency
	{mso-style-name:"Ref\. \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:8.5pt;
	font-family:"Verdana",sans-serif;}
p.SpecialcommentAgency, li.SpecialcommentAgency, div.SpecialcommentAgency
	{mso-style-name:"Special comment \(Agency\)";
	margin:0in;
	line-height:normal;
	font-size:8.5pt;
	font-family:"Verdana",sans-serif;
	color:red;}
p.TablefirstrowAgency, li.TablefirstrowAgency, div.TablefirstrowAgency
	{mso-style-name:"Table first row \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TableheadingAgency, li.TableheadingAgency, div.TableheadingAgency
	{mso-style-name:"Table heading \(Agency\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableFigurenoteAgency, li.TableFigurenoteAgency, div.TableFigurenoteAgency
	{mso-style-name:"Table\/Figure note \(Agency\)";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Verdana",sans-serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Calibri",sans-serif;}
span.UnresolvedMention1
	{mso-style-name:"Unresolved Mention1";
	color:#605E5C;
	background:#E1DFDD;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Calibri",sans-serif;}
span.UnresolvedMention2
	{mso-style-name:"Unresolved Mention2";
	color:#605E5C;
	background:#E1DFDD;}
span.Mention2
	{mso-style-name:Mention2;
	color:#2B579A;
	background:#E1DFDD;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Calibri",sans-serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Calibri",sans-serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Calibri",sans-serif;
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Calibri",sans-serif;
	color:green;
	font-style:normal;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Calibri",sans-serif;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Calibri",sans-serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;
	font-family:"Calibri",sans-serif;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Calibri",sans-serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Segoe UI",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";
	font-family:"Calibri",sans-serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-family:"Calibri",sans-serif;
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:Consolas;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	font-family:"Calibri",sans-serif;
	color:#4472C4;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:Consolas;}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Calibri Light",sans-serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";
	font-family:"Calibri",sans-serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:Consolas;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	font-family:"Calibri",sans-serif;
	color:#404040;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;
	font-family:"Calibri",sans-serif;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;
	font-family:"Calibri",sans-serif;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Calibri",sans-serif;
	color:#5A5A5A;
	letter-spacing:.75pt;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.9pt 70.55pt 56.9pt 70.55pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>"/>
                          </Binary>
                        </contained>
                        <!-- this exension is necessary per image -->
                        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                          <valueReference>
                            <reference value="#stylesheet0"/>
                          </valueReference>
                        </extension>
              
              <status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt"><img alt="BT_1000x858px" height="20" id="Picture 2" src="#image0" width="20"/></span><span style="font-size:11.0pt">This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span lang="FR" style="font-size:11.0pt">Zynteglo 1.2‑20 × 10<sup>6</sup> cells/mL dispersion for infusion. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="2.1     General description"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span lang="FR" style="font-size:11.0pt">Zynteglo (betibeglogene autotemcel) is a</span><span lang="FR" style="font-size:11.0pt"> genetically modified autologous CD34<sup>+ </sup>cell enriched population that contains haematopoietic stem cells (HSC) transduced with lentiviral vector (LVV) encoding the </span><span style="font-size:11.0pt">β</span><sup><span lang="FR" style="font-size:11.0pt">A‑T87Q</span></sup><span lang="FR" style="font-size:11.0pt">‑globin gene.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="2.2     Qualitative and quantitative composition"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The finished product is composed of one or more infusion bags which contain a dispersion of <span style="color:black">1.2‑20 × </span>10<sup>6 </sup><span style="color:black">cells/mL </span>suspended in cryopreservative solution<span style="color:black">. </span>Each infusion bag contains approximately 20 mL of Zynteglo.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The quantitative information regarding strength, CD34<sup>+</sup> cells, and dose for the medicinal product is provided in the Lot Information Sheet. The Lot Information Sheet is included inside the lid of the cryoshipper used to transport Zynteglo.  </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Excipient with known effect</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Each dose contains 391‑1564 mg sodium.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">For the full list of excipients, see section 6.1.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Dispersion for infusion.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">A clear to slightly cloudy, colourless to yellow or pink dispersion.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indication"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk500066939"><span style="font-size:11.0pt">Zynteglo is indicated for the treatment of patients 12 years and older with transfusion‑dependent β‑thalassaemia (TDT) who do not have a β<sup>0</sup>/β<sup>0</sup> genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)‑matched related HSC donor is not available (see sections 4.4 and 5.1).</span></a></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk497649473"><span style="font-size:11.0pt">Zynteglo must be administered in a qualified treatment centre by a physician(s) with experience in HSC transplantation and in the treatment of patients with TDT. </span></a><a name="_Hlk511314218"></a></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Patients are expected to enrol in a registry and will be followed in the registry in order to better understand the long-term safety and efficacy of Zynteglo. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt">Posology</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The minimum recommended dose of Zynteglo is 5.0 × 10<sup>6</sup> CD34<sup>+</sup> cells/kg. In clinical studies doses up to 20 × 10<sup>6</sup> CD34<sup>+</sup> cells/kg have been administered. The minimum recommended dose is the same for adults and adolescents 12 years of age and older.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo is intended for autologous use (see section 4.4) and should only be administered once.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><i><span style='font-family:"Times New Roman",serif'>Mobilisation and apheresis</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Patients are required to undergo HSC mobilisation followed by apheresis to obtain CD34<sup>+</sup> stem cells which will be used for medicinal product manufacturing (see section 5.1 for a description of the mobilisation regimen used in clinical studies). </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The minimum target number of CD34<sup>+</sup> cells to be collected is 12 × 10<sup>6</sup> CD34<sup>+</sup> cells/kg. If the minimum dose of Zynteglo of 5.0 × 10<sup>6</sup> CD34<sup>+</sup> cells/kg is not met after initial medicinal product manufacturing, the patient may undergo one or more additional cycles of mobilisation and apheresis, separated by at least 14 days, in order to obtain more cells for additional manufacture.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">A back-up collection of CD34<sup>+</sup> stem cells of ≥1.5 × 10<sup>6</sup> CD34<sup>+</sup> cells/kg (if collected by apheresis) or &gt;1.0 × 10<sup>8</sup> TNC/kg (if collected by bone marrow harvest) is required. These cells must be collected from the patient and be cryopreserved prior to myeloablative conditioning and infusion with Zynteglo. The back‑up collection may be needed for rescue treatment if there is: 1) compromise of Zynteglo after initiation of myeloablative conditioning and before Zynteglo infusion, 2) primary engraftment failure, or 3) loss of engraftment after infusion with Zynteglo (see section 4.4). </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><i><span style='font-family:"Times New Roman",serif'>Pre-treatment conditioning </span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The treating physician should confirm that HSC transplantation is appropriate for the patient before myeloablative conditioning is initiated (see section 4.4). </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt;color:black">Full myeloablative conditioning must be administered before infusion of Zynteglo (see section 5.1 for a description of the myeloablative regimen used in clinical studies). </span><span style="font-size:11.0pt">It is recommended that patients maintain haemoglobin (Hb) ≥11 g/dL for at least 30 days prior to mobilisation and during myeloablative conditioning. Iron chelation should be stopped at least 7 days prior to myeloablative conditioning. Prophylaxis for hepatic veno‑occlusive disease (VOD) is recommended. Prophylaxis for seizures should be considered (see section 5.1 for a description of the prophylaxis regimen used in clinical studies).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Myeloablative conditioning should not begin until the complete set of infusion bag(s) constituting the dose of Zynteglo has been received and stored at the administration site, and the availability of the back-up collection is confirmed. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><i><span style='font-family:"Times New Roman",serif'>Zynteglo administration</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">See Method of Administration below and section 6.6 for details on Zynteglo administration and handling.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><i><span style='font-family:"Times New Roman",serif'>After Zynteglo administration</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Any blood products required within the first 3 months after Zynteglo infusion should be irradiated. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Restarting iron chelation after Zynteglo infusion may be necessary and should be based on clinical practice (see sections 4.5 and 5.1). Phlebotomy can be used in lieu of iron chelation, when appropriate.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt">Special populations</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><i><u><span style="font-size:11.0pt"></span></u></i></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><i><span style="font-size:11.0pt">Elderly</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo has not been studied in patients &gt;65 years of age. HSC transplantation must be appropriate for a patient with TDT to be treated with Zynteglo (see section 4.4). No dose adjustment is required.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Renal impairment</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo has not been studied in patients with renal impairment. Patients should be assessed for renal impairment defined as creatinine clearance ≤70 mL/min/1.73 m<sup>2</sup> to ensure HSC transplantation is appropriate. No dose adjustment is required.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Hepatic impairment</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo has not been studied in patients with hepatic impairment. Patients should be assessed for hepatic impairment to ensure HSC transplantation is appropriate (see section 4.4.). No dose adjustment is required.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Paediatric population</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The safety and efficacy of Zynteglo in children &lt;12 years of age have not yet been established. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Patients seropositive for human immunodeficiency virus (HIV) or human T‑lymphotropic virus (HTLV)</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo has not been studied in patients with HIV‑1, HIV‑2, HTLV‑1, or HTLV‑2. A negative serology test for HIV is necessary to ensure acceptance of apheresis material for Zynteglo manufacturing. Apheresis material from patients with a positive test for HIV will not be accepted for Zynteglo manufacturing. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Method of administration </span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><u><span style="font-size:11.0pt"></span></u></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo is for intravenous use only (see section 6.6 for full details on the administration process).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">After completion of the 4‑day course of myeloablative conditioning, there must be a minimum of 48 hours of washout before Zynteglo infusion. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Before infusion, it must be confirmed that the patient’s identity matches the unique patient information on the Zynteglo infusion bag(s). The total number of infusion bags to be administered should also be confirmed with the Lot Information Sheet (see section 4.4).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo infusion should be completed as soon as possible and no more than 4 hours after thawing. Each infusion bag should be administered in less than 30 minutes. In the event that more than one infusion bag is provided, all infusion bags must be administered. The entire volume of each infusion bag should be infused. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Standard procedures for patient management after HSC transplantation should be followed after Zynteglo infusion.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Pregnancy and breast-feeding (see section 4.6).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Previous treatment with HSC gene therapy.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Contraindications to the mobilisation agents and the myeloablative conditioning agent must be considered.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><u><span style='font-family:"Times New Roman",serif'>Traceability</span></u></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><u><span style='font-family:"Times New Roman",serif'></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The traceability requirements of cell-based advanced therapy medicinal products must apply. To ensure traceability the name of the product, the batch number and the name of the treated patient should be kept for a period of 30 years.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">General</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Warnings and precautions of the mobilisation agents and the myeloablative conditioning agent must be considered.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Patients treated with Zynteglo should not donate blood, organs, tissues or cells for transplantation at any time in the future. This information is provided in the Patient Alert Card which must be given to the patient after treatment. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo is intended solely for autologous use and must not be administered to other patients. Confirm that the patient’s identity matches the unique patient identification information on the Zynteglo infusion bag(s) and metal cassette(s). Do not infuse Zynteglo if the information on the patient specific label on the infusion bag(s) or metal cassette(s) do not match the intended patient.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Risks associated with TDT and iron overload</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif'>Patients with TDT experience iron overload due to chronic red blood cell (RBC) transfusions that can lead to end organ damage. HSC transplantation with myeloablative conditioning is not appropriate for patients with TDT who have evidence of severely elevated iron in the heart i.e., patients with cardiac T2* &lt;10 msec by magnetic resonance imaging (MRI). MRI of the liver should be performed on all patients prior to myeloablative conditioning. It is recommended that patients with MRI results demonstrating liver iron content ≥15 mg/g undergo liver biopsy for further evaluation. If the liver biopsy demonstrates bridging fibrosis, cirrhosis, or active hepatitis, HSC transplantation with myeloablative conditioning is not appropriate.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Risk of insertional oncogenesis</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">No cases of leukaemia or lymphoma have been reported in clinical studies with Zynteglo in patients with TDT. There are no reports of LVV‑mediated insertional mutagenesis resulting in oncogenesis. Nevertheless, there is a theoretical risk of leukaemia or lymphoma after treatment with Zynteglo. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Patients should be monitored annually for leukaemia or lymphoma (including with a complete blood count) for 15 years post treatment with Zynteglo. If leukaemia or lymphoma is detected in any patient who received Zynteglo, blood samples should be collected for integration site analysis.  </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Serological testing</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">All patients should be tested for HIV-1/2 prior to mobilisation and apheresis to ensure acceptance of the apheresis material for Zynteglo manufacturing (see section 4.2). </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Interference with serology testing</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">It is important to note that patients who have received Zynteglo are likely to test positive by polymerase chain reaction (PCR) assays for HIV due to LVV provirus insertion, resulting in a false positive test for HIV. Therefore, patients who have received Zynteglo should not be screened for HIV infection using a PCR-based assay. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt">Engraftment failure as measured by neutrophil engraftment</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Treatment with Zynteglo involves the infusion and engraftment of CD34<sup>+</sup> HSCs that have been genetically modified <i>ex vivo</i> with a LVV. In clinical trials, no patients failed to engraft bone marrow, as measured by neutrophil engraftment (N=45). <span style="color:black">Neutrophil engraftment occurred on median (min, max) Day 21.0 (13, 38) after medicinal product infusion. </span>Failure of neutrophil engraftment is a short-term but potentially severe risk, defined as failure to achieve 3 consecutive absolute neutrophil counts (ANC) ≥500 cells/µL obtained on different days by Day 43 after infusion of Zynteglo. Patients who experience neutrophil engraftment failure should receive rescue treatment with the back-up collection (see section 4.2).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Delayed platelet engraftment</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Platelet engraftment is defined as 3 consecutive platelet values ≥20 × 10<sup>9</sup>/L obtained on different days after Zynteglo infusion, with no platelet transfusions administered for 7 days immediately preceding and during the evaluation period.<b></b>Patients with TDT treated with Zynteglo who achieved platelet engraftment had a median (min, max) platelet engraftment on Day 42.0 (19, 191) in clinical trials (N=45). No correlation was observed between incidence of bleeding and delayed platelet engraftment. Patients should be made aware of the risk of bleeding until platelet recovery has been achieved. Patients should be monitored for thrombocytopenia and bleeding according to standard guidelines. Platelet counts should be monitored according to medical judgment until platelet engraftment and platelet recovery are achieved. Blood cell count determination and other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Anti-retroviral and hydroxyurea use</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Patients should not take anti‑retroviral medications or hydroxyurea from at least one month prior to mobilisation until at least 7 days after Zynteglo infusion (see section 4.5). <a name="_Hlk3111940">If a patient requires anti‑retrovirals for HIV prophylaxis, Zynteglo treatment, including mobilisation and apheresis of CD34</a></span><sup>+</sup><span style="font-size:11.0pt"> cells through Zynteglo infusion, should be delayed until an HIV infection could be adequately ruled out according to local guidance for HIV testing.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Sodium content</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">This medicinal product contains 391‑1564 mg sodium per dose equivalent to 20 to 78% of the WHO recommended maximum daily intake of 2 g sodium for an adult. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Patients should not take anti‑retroviral medicinal products or hydroxyurea from at least one month prior to mobilisation until at least 7 days after Zynteglo infusion (see section 4.4).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Drug-drug interactions between iron chelators and the myeloablative conditioning agent must be considered. Iron chelators should be discontinued 7 days prior to initiation of conditioning. The Summary of Product Characteristics (SmPC) for the iron chelator and the myeloablative conditioning agent must be consulted for the recommendations regarding co-administration with CYP3A substrates.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Some iron chelators are myelosuppressive. After Zynteglo infusion, avoid use of these iron chelators for 6 months. If iron chelation is needed, consider administration of non-myelosuppressive iron chelators (see sections 4.2 and 5.1).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">No formal drug interaction studies have been performed. Zynteglo is not expected to interact with the hepatic cytochrome P‑450 family of enzymes or drug transporters.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">There is no clinical experience with the use of erythropoiesis-stimulating agents in patients treated with Zynteglo.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The safety of immunisation with live viral vaccines during or following Zynteglo treatment has not been studied. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after: avoid"></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt">Women of childbearing potential/Contraception in males and females</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt;color:black">There are insufficient exposure data to provide a precise recommendation on duration of </span><span style="font-size: 11.0pt">contraception following treatment with Zynteglo. Women of childbearing potential and men capable of fathering a child must use a reliable method of contraception (intra-uterine device or combination of hormonal and barrier contraception) from start of mobilisation through at least 6 months after administration of Zynteglo. Consult the SmPC of the myeloablative conditioning agent for information on the need for effective contraception in patients who undergo conditioning. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Pregnancy</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">A negative serum pregnancy test must be confirmed prior to the start of mobilisation and re-confirmed prior to conditioning procedures and before medicinal product administration.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">No clinical data on exposed pregnancies are available.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Reproductive and developmental toxicity studies with Zynteglo were not performed. Zynteglo must not be used during pregnancy because of myeloablative conditioning (see section 4.3). It is unknown whether Zynteglo transduced cells have the potential to be transferred in utero to a foetus.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">There is no opportunity for germline transmission of the β<sup>A‑T87Q</sup>‑globin gene after treatment with Zynteglo, therefore the likelihood that an offspring would have general somatic expression of the β<sup>A‑T87Q</sup>‑globin gene is considered negligible.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Breast-feeding</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">It is unknown whether Zynteglo is excreted in human milk. The effect of administration of Zynteglo to mothers on their breast-fed children has not been studied.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo must not be administered to women who are breast-feeding.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Fertility</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">There are no data on the effects of Zynteglo on human fertility. Effects on male and female fertility have not been evaluated in animal studies. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Data are available on the risk of infertility with myeloablative conditioning. <span style="color:black">It is therefore advised to cryopreserve semen or ova before treatment if possible.</span></span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo has no influence on the ability to drive or use machines.<br/> <br/> </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The effect of the mobilisation agents and the myeloablative conditioning agent on the ability to drive or use machines must be considered.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Summary of the safety profile</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The safety of Zynteglo was evaluated in 45 patients with TDT. The only serious adverse reaction attributed to Zynteglo was thrombocytopenia (2.2%). <span style="color:black">Given the small patient population and size of cohorts, adverse reactions in the table below do not provide a complete perspective on the nature and frequency of these events. </span></span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt">Tabulated list of adverse reactions<br/> <br/> </span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Adverse reactions are listed by MedDRA body system organ class and by frequency convention. Frequencies are defined as: very common <span style="color:#323232">(≥1/10), and c</span>ommon (≥1/100 to &lt;1/10). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Tables 1, 2, and 3 are lists of adverse reactions attributed to mobilisation/apheresis, myeloablative conditioning, and Zynteglo, respectively, experienced by patients with TDT in clinical trials with Zynteglo.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-after:avoid; text-autospace:none"><b><span style='font-family:"Times New Roman",serif'>Table 1              Adverse reactions attributed to mobilisation/apheresis</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="border-collapse:collapse;border:none"> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><a name="_Hlk4086514"><b><span style='font-family:"Times New Roman",serif'>System   Organ Class (SOC)</span></b></a></p> </td> <td style="width:151.4pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><b><span style='font-family:"Times New Roman",serif'>Very Common (≥10%)</span></b></p> </td> <td style="width:151.4pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><b><span style='font-family:"Times New Roman",serif'>Common (≥1% - &lt;10%)</span></b></p> </td> </tr> <tr style="height:8.5pt"> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Blood and lymphatic   system disorders</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Thrombocytopenia</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Splenomegaly,   Leukocytosis</span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Metabolism and   nutrition disorders</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Hypocalcaemia</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Hypokalaemia,   Hypomagnesaemia</span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Psychiatric disorders</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Agitation</span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Nervous system   disorders</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Headache, Peripheral   sensory neuropathy</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Dizziness, Head   discomfort, Paraesthesia</span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Cardiac disorders</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Cardiac flutter</span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Vascular disorders</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Hypotension</span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Respiratory, thoracic   and mediastinal disorders</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Hypoxia, Epistaxis</span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Gastrointestinal   disorders</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Nausea</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Vomiting, Lip   swelling, Abdominal pain, Abdominal pain upper, Paraesthesia oral </span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Skin and subcutaneous   tissue disorders</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Rash, Hyperhidrosis</span></p> </td> </tr> <tr style="height:22.9pt"> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Musculoskeletal and   connective tissue disorders</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:22.9pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Bone pain</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:22.9pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Back pain,   Musculoskeletal discomfort</span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>General disorders and   administration site conditions</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Pyrexia, Influenza   like illness, Chest discomfort, Chest pain, Injection site reaction, Catheter   site haemorrhage, Catheter site bruise, Injection site bruising, Fatigue,   Non-cardiac chest pain, Catheter site pain, Injection site pain, Puncture   site pain, Pain</span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Investigations</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Blood magnesium   decreased</span></p> </td> </tr> <tr> <td style="width:150.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Injury, poisoning and   procedural complications</span></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Citrate toxicity,   Contusion, Procedural pain</span></p> </td> </tr> </table><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-before:always; page-break-after:avoid;text-autospace:none"><a name="_Hlk4086533"><b><span style='font-family:"Times New Roman",serif'>Table 2              Adverse reactions attributed to myeloablative conditioning</span></b></a></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="border-collapse:collapse;border:none"> <thead> <tr style="height:10.3pt"> <td style="width:151.25pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:10.3pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><b><span style='font-family:"Times New Roman",serif'>SOC</span></b></p> </td> <td style="width:151.25pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.3pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><b><span style='font-family:"Times New Roman",serif'>Very Common (≥10%)</span></b></p> </td> <td style="width:151.25pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.3pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><b><span style='font-family:"Times New Roman",serif'>Common (≥1% - &lt;10%)</span></b></p> </td> </tr> </thead> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Infections and   infestations</span></p> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Neutropenic sepsis,   Systemic infection, Staphylococcal infection, Pneumonia, Lower respiratory   tract infection, Urinary tract infection, Mucosal infection, Cellulitis,   Vaginal infection, Rash pustular, Folliculitis, Gingivitis, Vulvovaginal   candidiasis</span></p> </td> </tr> <tr style="height:8.5pt"> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span style='font-family:"Times New Roman",serif;color:black'>Blood   and lymphatic system disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span lang="IT" style='font-family:"Times New Roman",serif;color:black'>Febrile   neutropenia, Neutropenia, Thrombocytopenia, Leukopenia, Anaemia</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span style='font-family:"Times New Roman",serif;color:black'>Lymphopenia,   Leukocytosis, Monocyte count decreased, Neutrophilia, Mean cell haemoglobin   concentration increased</span></p> </td> </tr> <tr style="height:8.5pt"> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span style='font-family:"Times New Roman",serif;color:black'>Endocrine   disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span style='font-family:"Times New Roman",serif;color:black'>Primary   hypogonadism</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Metabolism and nutrition   disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Decreased appetite</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Hypocalcaemia,   Hypokalaemia, Metabolic acidosis, Fluid overload, Fluid retention,   Hypomagnesaemia, Hyponatraemia, Hypophosphataemia, Hyperphosphataemia</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Psychiatric disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Insomnia</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Anxiety</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Nervous system   disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Headache</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Dizziness, Lethargy,   Dysgeusia, Ageusia, Memory impairment</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Eye disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Conjunctival   haemorrhage</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Ear and labyrinth   disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Vertigo</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Cardiac disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Cardiac failure   congestive, Atrial fibrillation </span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Vascular disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Hypotension,   Haematoma, Hot flush</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Respiratory, thoracic   and mediastinal disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Epistaxis, Pharyngeal   inflammation</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Hypoxia, Pulmonary   mass, Dyspnoea, Pleural effusion, Rales, Upper-airway cough syndrome, Cough,   Laryngeal pain, Hiccups, Oropharyngeal pain </span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Gastrointestinal   disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Stomatitis, Vomiting,   Nausea, Diarrhoea, Gingival bleeding, Constipation, Abdominal pain, Anal   inflammation </span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Anal haemorrhage,   Gastritis, Gastrointestinal inflammation, Abdominal distension, Abdominal   pain upper, Anal fissure, Dyspepsia, Dysphagia, Oesophagitis, Haemorrhoids,   Proctalgia, Lip dry</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Hepatobiliary   disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Veno‑occlusive   liver disease, Alanine aminotransferase increased, Aspartate aminotransferase   increased, Blood bilirubin increased</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Cholecystitis,   Cholelithiasis, Hepatomegaly, Jaundice, Transaminases increased,   Gamma-glutamyltransferase increased</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Skin and subcutaneous   tissue disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Alopecia, Pruritus,   Skin hyperpigmentation</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Petechiae,   Ecchymosis, Pain of skin, Palpable purpura, Pigmentation disorder, Pruritus   generalised, Purpura, Sweat gland disorder, Urticaria, Dry skin, Rash</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Musculoskeletal and   connective tissue disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Bone pain, Myalgia,   Pain in extremity, Back pain</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Renal and urinary   disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Haematuria,   Pollakiuria</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Reproductive system   and breast disorders</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Vaginal haemorrhage</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Ovarian failure,   Menstruation irregular, Premature menopause, Blood follicle stimulating   hormone increased, Blood testosterone decreased</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>General disorders and   administration site conditions</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Pyrexia, Fatigue,   Mucosal inflammation</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Face oedema,   Hypothermia, Feeling cold, Pain, Xerosis</span></p> </td> </tr> <tr> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span style='font-family:"Times New Roman",serif;color:black'>Investigations</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span style='font-family:"Times New Roman",serif;color:black'>C‑reactive   protein increased, Aspergillus test positive, Blood potassium decreased,   Weight decreased, Blood alkaline phosphatase decreased, Blood magnesium   decreased, Forced expiratory flow decreased, Protein total decreased, Blood   albumin decreased, Reticulocyte count decreased, Reticulocyte percentage   decreased</span></p> </td> </tr> <tr style="height:23.8pt"> <td style="width:151.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.8pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Injury, poisoning and   procedural complications</span></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.8pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:151.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.8pt" valign="top" width="202"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Transfusion reaction,   Skin abrasion</span></p> </td> </tr> </table><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-after:avoid; text-autospace:none"><b><span style='font-family:"Times New Roman",serif'>Table 3              Adverse reactions attributed to Zynteglo</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="width:451.75pt;border-collapse:collapse;border:none" width="602"> <tr style="height:14.35pt"> <td style="width:150.55pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><b><span style='font-family:"Times New Roman",serif'>SOC</span></b></p> </td> <td style="width:150.6pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><b><span style='font-family:"Times New Roman",serif'>Very Common (≥10%)</span></b></p> </td> <td style="width:150.6pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><b><span style='font-family:"Times New Roman",serif'>Common (≥1% - &lt;10%)</span></b></p> </td> </tr> <tr style="height:9.4pt"> <td style="width:150.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Blood and lymphatic   system disorders</span></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.4pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Thrombocytopenia, </span></p> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Leukopenia,   Neutropenia</span></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:150.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Vascular disorders</span></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Hot flush</span></p> </td> </tr> <tr style="height:14.05pt"> <td style="width:150.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.05pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Respiratory, thoracic   and mediastinal disorders</span></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.05pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.05pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Dyspnoea</span></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:150.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Gastrointestinal   disorders</span></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Abdominal pain</span></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:150.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Musculoskeletal and   connective tissue disorders</span></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Pain in extremity</span></p> </td> </tr> <tr style="height:28.5pt"> <td style="width:150.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.5pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>General disorders and   administration site conditions</span></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.5pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p> </td> <td style="width:150.6pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.5pt" valign="top" width="201"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif;color:black'>Non-cardiac chest   pain</span></p> </td> </tr> </table><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Description of selected adverse reactions</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk4059620"><i><span style="font-size:11.0pt">Bleeding</span></i></a></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Bleeding is a potential complication of thrombocytopenia subsequent to myeloablative conditioning and treatment with Zynteglo. The majority of all reported bleeding events were nonserious. A risk of bleeding exists before platelet engraftment and may continue after platelet engraftment in patients who have continued thrombocytopenia.   </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Following platelet engraftment, all patients maintained platelet levels of ≥20 × 10<sup>9</sup>/L. Median (min, max) times to unsupported platelet counts of ≥50 × 10<sup>9</sup>/L  and ≥100 × 10<sup>9</sup>/L were 51 (20, 268) days (N=45) and 63.5 (20, 1231) days (N=42), respectively (see section 4.4 for guidance on platelet monitoring and management).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Hepatic veno-occlusive disease</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Serious events of hepatic VOD occurred in 11.1% of patients following myeloablative conditioning; 80% of these patients did not receive prophylaxis for VOD. All patients who experienced VOD received treatment with defibrotide and recovered. Patients with TDT may be at an increased risk of VOD following myeloablative conditioning compared with other patient populations.  </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><i><span style="font-size:11.0pt">Infusion related reactions to Zynteglo</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><span style="font-size:11.0pt">Pre-medication for infusion reactions was managed at physician discretion. Infusion related reactions to Zynteglo were observed in 13.3% of patients and occurred on the day of Zynteglo infusion. All reactions resolved and the majority were mild. Events included abdominal pain, dyspnoea, hot flush, and non‑cardiac chest pain in 11.1%, 2.2%, 2.2%, and 2.2% of patients, respectively.  </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt">Paediatric population</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk3021378"></a><a name="_Hlk2980904"><span style="font-size:11.0pt">According to available data, the frequency, type, and severity of adverse reactions in adolescents 12‑17 years of age are similar to adults with the exception that VOD and pyrexia occurred more frequently in adolescents.</span></a></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Reporting of suspected adverse reactions</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background:lightgrey">the national reporting system listed in <span class="MsoHyperlink">Appendix V</span>.</span></span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">No data from clinical studies are available regarding overdose of Zynteglo. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Pharmacotherapeutic group: Other haematological agents, ATC code: B06AX02</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Mechanism of action</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo adds functional copies of a modified β-globin gene into the patients’ HSCs through transduction of autologous CD34<sup>+</sup> cells with BB305 LVV, thereby addressing the underlying genetic cause of the disease. After Zynteglo infusion, transduced CD34<sup>+</sup> HSCs engraft in the bone marrow and differentiate to produce RBCs containing biologically active <span style="color:black">β<sup>A‑T87Q</sup>‑globin (a modified β‑globin protein) that will combine with α-globin to produce functional Hb containing </span>β<sup>A‑T87Q</sup>‑globin (Hb<span style="color:black">A<sup>T87Q</sup>). </span>β<sup>A‑T87Q</sup>‑globin can be quantified relative to other globin species in peripheral blood using high performance liquid chromatography.β<sup>A‑T87Q</sup>‑globin expression is designed to correct the β/α‑globin imbalance in erythroid cells of patients with TDT and has the potential to increase total Hb to normal levels and eliminate dependence on chronic RBC transfusions. <a name="_Hlk2981031">Following successful engraftment and achievement of transfusion independence, the effects of the product are expected to be life‑long.</a></span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Pharmacodynamic effects </span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">All patients with TDT with a non‑β<sup>0</sup>/β<sup>0</sup> genotype who received Zynteglo with at least 3 months of follow-up produced HbA<sup>T87Q</sup> (N=10, HGB‑204; N=4, HGB‑205; N=15, HGB‑207; N=3, HGB‑212). For patients with at least 6 months of follow-up, HbA<sup>T87Q</sup> generally increased steadily after Zynteglo infusion and stabilised by approximately Month 6. Patients had a Month 6 median (min, max) HbA<sup>T87Q</sup> of 4.901 (1.03, 9.59) g/dL in the Phase 1/2 studies (N=14, HGB‑204 and HGB‑205) and 9.409 (3.35, 10.60) g/dL in ongoing Phase 3 studies (N=16, HGB‑207 and HGB-212).  </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">HbA<sup>T87Q</sup> remained generally stable through Month 24 with a median (min, max) of 6.444 (1.10, 10.13) g/dL in the completed Phase 1/2 studies (N=14, HGB‑204 and HGB‑205) and 8.766 (0.89, 11.40) g/dL in the ongoing Phase 3 studies (N=3, HGB‑207). HbA<sup>T87Q</sup> continued to be stable at last follow-up through Month 60, demonstrating stable integration of the β<sup>A‑T87Q</sup>‑globin gene into long‑term HSCs and stable expression of the β<sup>A‑T87Q</sup>‑globin gene in cells of the erythroid lineage. <a name="IDX"></a></span></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal;text-autospace: none"></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><a name="_Hlk535595211"><u><span style="font-size:11.0pt">Clinical efficacy </span></u></a></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Efficacy was based on 32 adult and adolescent patients with TDT and a non‑β<sup>0</sup>/β<sup>0</sup> genotype treated with Zynteglo (N=10, HGB‑204; N=4, HGB‑205; N=15, HGB‑207; N=3, HGB‑212) (see Table 4). <a name="_Hlk2977601">A few patients have been included in the clinical studies with genotypes characterised by low endogenous β‑globin production phenotypically similar to patients with a β<sup>0</sup>/β<sup>0</sup> genotype, such as patients homozygous for IVS‑I‑110 or IVS‑I‑5. </a></span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;text-indent:-1.0in;line-height:normal"><b><span style="font-size:11.0pt">Table 4              Baseline characteristics for non‑β<sup>0</sup>/β<sup>0</sup> patients with TDT ≥12 years of age treated with Zynteglo (Studies HGB‑204, HGB‑205, HGB‑207, HGB‑212, LTF‑303)          </span></b></p><p class="C-BodyText" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;text-indent:-1.0in;line-height:normal"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="border-collapse:collapse;border:none"> <tr style="height:48.6pt"> <td style="width:62.5pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:48.6pt" valign="top" width="83"> <p class="C-BodyText" style="margin:0in;line-height:normal"><b><span style="font-size:11.0pt">Study</span></b></p> </td> <td style="width:76.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt" valign="top" width="102"> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><b><span lang="EN-GB" style="font-size:11.0pt">Total number   of patients </span></b></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">(young adults/ adolescents)</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"></p> </td> <td style="width:67.6pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt" valign="top" width="90"> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><b><span style="font-size:11.0pt">Age</span></b></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(years)</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">median (min, max)</span></p> </td> <td style="width:121.85pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt" valign="top" width="162"> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><b><span style="font-size:11.0pt">Pre-enrolment   transfusion volumes</span></b></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(mL/kg/year)</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">median (min, max)</span></p> </td> <td style="width:125.15pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt" valign="top" width="167"> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><b><span style="font-size:11.0pt">Pre-enrolment   transfusion frequency</span></b></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(number/year)</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">median (min, max)</span></p> </td> </tr> <tr style="height:11.9pt"> <td style="width:62.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="83"> <p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">HGB‑205</span></p> </td> <td style="width:76.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="102"> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">4</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(2)</span></p> </td> <td style="width:67.6pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>young   adults/ adolescents*</span></p> </td> <td style="width:121.85pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>181.85</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>(138.8,   197.3)</span></p> </td> <td style="width:125.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="167"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>12.50</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>(10.5,   13.0) </span></p> </td> </tr> <tr style="height:11.9pt"> <td style="width:62.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="83"> <p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">HGB‑204</span></p> </td> <td style="width:76.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="102"> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">10</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(2)</span></p> </td> <td style="width:67.6pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>19.5</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(16, 34)</span></p> </td> <td style="width:121.85pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>151.28</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(140.0, 234.5)</span></p> </td> <td style="width:125.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="167"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>13.75</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(10.0, 16.5)</span></p> </td> </tr> <tr style="height:11.9pt"> <td style="width:62.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="83"> <p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">HGB‑207</span></p> </td> <td style="width:76.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="102"> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">15</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(6)</span></p> </td> <td style="width:67.6pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>20.0</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(12, 34)</span></p> </td> <td style="width:121.85pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>192.92</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(152.3, 251.3)</span></p> </td> <td style="width:125.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.9pt" valign="top" width="167"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>17.50</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(11.5, 37.0)</span></p> </td> </tr> <tr style="height:12.3pt"> <td style="width:62.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.3pt" valign="top" width="83"> <p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">HGB‑212</span></p> </td> <td style="width:76.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.3pt" valign="top" width="102"> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">3</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(1)</span></p> </td> <td style="width:67.6pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.3pt" valign="top" width="90"> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span lang="PT">adults/ adolescents*</span></p> </td> <td style="width:121.85pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.3pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>175.51</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(170.7, 209.6)</span></p> </td> <td style="width:125.15pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.3pt" valign="top" width="167"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>21.50</span></p> <p align="center" class="C-BodyText" style="margin:0in;text-align:center;   line-height:normal"><span style="font-size:11.0pt">(17.5, 39.5)</span></p> </td> </tr> </table><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">*Age range is not provided to protect patient identity.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Transfusion‑dependent β‑thalassaemia (TDT)</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk2977740"></a></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Patients were considered to be transfusion‑dependent if they had a history of transfusions of at least 100 mL/kg/year of RBCs or with ≥8 transfusions of RBCs per year in the 2 years preceding enrolment. In the clinical studies, patients received a median (min, max) RBC transfusion volume of 175.74 (138.8, 251.3) mL/kg/year and a median (min, max) number of 14.75 (10.0, 39.5) RBC transfusions per year. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Adolescents were excluded from Phase 3 studies if they had a known and available HLA‑matched related HSC donor. The median (min, max) age in the studies was 19.0 (12, 34) years, 56.3% were females, 59.4% were Asian, and 40.6% White/Caucasian. All patients had a Karnofsky/Lansky performance score ≥80 and the majority (18/32, 56.3%) had a performance score of 100 at baseline. Cardiac T2* at baseline was &gt;20 msec. The median (min, max) serum ferritin at baseline was 3778.7 (784, 22517) pmol/L and median (min, max) liver iron concentration was 6.75 (1.0, 41.0) mg/g (N=10, HGB‑204; N=4, HGB‑205; N=15, HGB‑207; N=3, HGB‑212).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Mobilisation and apheresis</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk433984"></a></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">All patients were administered G‑CSF and plerixafor to mobilise stem cells prior to the apheresis procedure. The planned dose of G‑CSF was 10 µg/kg/day in patients with a spleen, and 5 µg/kg/day in patients without a spleen, given on Days 1 through 5 of mobilisation in the morning. The planned dose of plerixafor was 0.24 mg/kg/day, given on Days 4 and 5 of mobilisation in the evening. If a third day of collection was needed, plerixafor and G‑CSF dosing was extended to Day 6. The dose of G‑CSF was decreased by half if white blood cell (WBC) count was &gt;100 × 10<sup>9</sup>/L prior to the day of apheresis. For most patients, the minimum number of CD34<sup>+</sup> cells to manufacture Zynteglo was collected with 1 cycle of mobilisation and apheresis. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><i><span style="font-size:11.0pt">Pre-treatment conditioning</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><span style="font-size:11.0pt">All patients received full myeloablative conditioning with busulfan prior to treatment with Zynteglo. The planned dose of busulfan was 3.2 mg/kg/day for patients ≥18 years as a 3‑hour IV infusion daily for 4 days with a recommended target AUC<sub>0-24h </sub>of 3800‑4500 µM*min. The planned dose of busulfan was 0.8 mg/kg for patients 12‑17 years of age as a 2‑hour IV infusion every 6 hours for a total of 16 doses with a recommended target of AUC<sub>0-6h </sub>of 950‑1125 µM*min. The busulfan SmPC was used for information on appropriate method for determination of patient weight‑based dosing. <a name="_Hlk2978225">Busulfan dose adjustments were made as needed based on pharmacokinetic monitoring.</a></span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The median (min, max) busulfan dose was 3.50 (2.5, 5.0) mg/kg/day (N=32). AUC<sub>0-24h</sub> was measured during Day 1 and informed the dose for Day 3; the median (min, max) estimated daily AUC was 4394.5 (3030, 9087) μM*min (N=32). All patients with non‑β<sup>0</sup>/β<sup>0</sup> genotypes received anti-seizure prophylaxis with agents other than phenytoin prior to initiating busulfan. Phenytoin was not used for anti-seizure prophylaxis because of its well understood induction of glutathione‑S‑transferase and cytochrome P450 and resultant increased clearance of busulfan, and because of the widespread availability of effective anti‑seizure medications that do not affect busulfan metabolism.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">In HGB‑207 and HGB‑212 prophylaxis for VOD/hepatic sinusoidal obstruction syndrome was required per institutional practice with ursodeoxycholic acid or defibrotide. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Zynteglo administration</span></i></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">All patients were administered Zynteglo with a median (min, max) dose of 7.80 × 10<sup>6 </sup>(5.0, 19.4) CD34<sup>+</sup> cells/kg as an intravenous infusion (N=32).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk956286"></a><a name="_Hlk955665"><i><span style="font-size:11.0pt">After Zynteglo administration</span></i></a></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">A total of 31.1% of patients (14/45; HGB‑204, HGB‑205, HGB‑207, HGB‑212) received G‑CSF within 21 days after Zynteglo infusion</span><span style="font-size:11.0pt">. However, G‑CSF use was not recommended for 21 days after Zynteglo infusion in Phase 3 studies.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Studies HGB‑204 and HGB‑205</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">HGB‑204 and HGB‑205 were Phase 1/2 open-label, single-arm 24‑month studies that included 22 patients with TDT treated with Zynteglo (N=18, HGB‑204; N=4, HGB‑205), of whom 14 had a non‑β<sup>0</sup>/β<sup>0</sup> genotype (N=10, HGB‑204; N=4, HGB‑205) and 8 had a β<sup>0</sup>/β<sup>0</sup> genotype in HGB‑204. All patients completed HGB‑204 and HGB‑205 and enrolled for long‑term follow‑up in the LTF‑303 study. The median (min, max) duration of follow-up of patients with a non‑β<sup>0</sup>/β<sup>0</sup> genotype was 44.63 (35.8, 61.3)months. <a name="_Hlk4078994">All patients remain alive at last follow-up.   </a></span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The primary endpoint was transfusion independence (TI) by Month 24, defined as a weighted average Hb ≥9 g/dL without any RBC transfusions for a continuous period of ≥12 months at any time during the study after infusion of Zynteglo. Of the patients with a non‑β<sup>0</sup>/β<sup>0</sup> genotype, 11/14 (78.6%, 95% CI 49.2%‑95.3%) achieved TI by Month 24 (Table 5). Among these 11 patients, the median (min, max) weighted average Hb during TI was 10.51 (9.3, 13.3) g/dL (Table 5). </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">All patients who have achieved TI at any time have maintained TI at Month 36 with a min, max duration of TI of 28.3+, 57.6+ months (N=11). The median (min, max) time to last RBC transfusion was 0.46 (0.2, 5.8)months following Zynteglo infusion. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">In the 3 patients who did not achieve TI, reductions of 100%, 86.9% and 26.8% in transfusion volume requirements and of 100%, 85.3% and 20.7% in transfusion frequency were observed between Month 6 through Month 24 visit when compared to their pre-study levels of RBC transfusions. Reductions in volume and frequency were maintained at last follow‑up in LTF‑303.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The median (min, max) total Hb at Month 6 for patients who had not received a transfusion for the prior 60 days was 10.60 (7.6, 13.4) g/dL (N=11). Total Hb remained stable at Month 24 with a median (min, max) of 10.60 (8.8, 13.7) g/dL (N=12) and at Month 36 with a median (min, max) of 10.60 (7.8, 13.5) g/dL (N=13). </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="MsoCommentText" style="margin-bottom:0in;line-height:normal"><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>After Zynteglo infusion, patient iron chelation was managed at physician discretion. Of the 14 non‑β<sup>0/</sup>β<sup>0</sup> patients treated in HGB‑204 and HGB‑205 that completed Month 6, 9 patients (64.3%) reported ongoing chelation use at last follow-up. The remaining 5 patients (35.7%) had stopped iron chelation, of whom 4 patients (28.6%) have stopped chelation for at least 6 months with median (min, max) time from stopping chelation to last follow-up of 26.40 (11.5, 42.2) months for these 4 patients. Additionally, of the 14 treated patients, 3 patients in HGB‑205 (21.4%) received phlebotomy to remove iron. For the 11 patients that achieved TI, 4 patients (36.4%) stopped chelation for at least 6 months and 3 patients (27.3%) received phlebotomy.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk4398701"><span style="font-size:11.0pt">At 48 months after infusion of Zynteglo for patients who achieved TI, the median reduction (min, max) in serum ferritin levels from baseline was 70.00% (39.2, 84.8) (N=5, HGB‑204; N=2, HGB‑205). The median reduction in liver iron content from baseline was 62.50%, ranging from an 83.3% reduction to a 269.2% increase (N=5, HGB‑204; N=2, HGB‑205).</span></a></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Studies HGB‑207 and HGB‑212</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk774161"><span style="font-size:11.0pt">HGB‑207 and HGB‑212 are ongoing Phase 3 open‑label, single-arm 24‑month studies that are planned to include approximately 39 adults, adolescents, and children with TDT (N=23, HGB‑207; N=16, HGB‑212), of whom 29 have a non‑β<sup>0</sup>/β<sup>0</sup> genotype (N=23, HGB‑207; N=6, HGB‑212) and 10 have a β<sup>0</sup>/β<sup>0</sup> genotype in HGB‑212. </span></a><span style="font-size:11.0pt">These studies are conducted with improved transduction compared to Phase 1/2 studies, resulting in increased average number of functional copies of the transgene (β<sup>A‑T87Q</sup>‑globin) integrated in the autologous CD34<sup>+</sup> cells. <a name="_Hlk4244937">Eighteen adults and adolescents with TDT with a non‑β<sup>0</sup>/β<sup>0</sup> genotype have been treated with Zynteglo in Phase 3 studies (N=15, HGB‑207; N=3, HGB‑212) and their median (min, max) duration of follow-up was 15.92 (5.6, 26.3) months.</a> <a name="_Hlk4079020">All patients remain alive at last follow‑up.</a></span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The primary endpoint was transfusion independence (TI) by Month 24, defined as a weighted average Hb ≥9 g/dL without any RBC transfusions for a continuous period of ≥12 months at any time during the study after infusion of Zynteglo. Ten patients are evaluable for assessment of TI. Of these, 9/10 (90.0%, 95% CI 55.5‑99.7%) achieved TI at last follow‑up. Among these 9 patients, the median (min, max) weighted average Hb during TI was 12.22 (11.4, 12.8) g/dL (Table 5). </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">All patients who have achieved TI have maintained TI with a min, max duration of TI of 12.1+, 21.3+ months (N=9). The median (min, max) time to last RBC transfusion was 1.08 (0.5, 2.2) months following Zynteglo infusion. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk517114053"><span style="font-size:11.0pt">For the only patient who did not achieve TI, a reduction of 51.5% in transfusion volume requirements and a reduction of 43.4% in transfusion frequency were observed from Month 12 to Month 24 when compared to their pre-study levels of RBC transfusions. </span></a></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The median (min, max) total Hb at Month 6 for patients who had not received a transfusion for the prior 60 days was 11.85 (8.4, 13.3) g/dL (N=18). Total Hb remained stable at Month 24 with a median (min, max) of 12.85 (12.5, 13.2) g/dL (N=2).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Hlk536092762"><span style="font-size:11.0pt">After Zynteglo infusion, patient iron chelation was managed at physician discretion. Of the 18 non‑β<sup>0</sup>/β<sup>0</sup> patients treated in HGB‑207 and HGB‑212 that completed Month 6, 5 patients (27.8%) reported ongoing chelation use at last follow-up. The remaining 13 patients (72.2%) had stopped iron chelation, of whom 9 patients (50.0%) have stopped chelation for at least 6 months with median (min, max) time from stopping chelation to last follow-up of 16.89 (6.9, 25.4) months for these 9 patients. Additionally, of the 18 treated patients, 5 patients in HGB‑207 (27.8%) received phlebotomy to remove iron. For the 9 patients that achieved TI, 6 patients (66.7%) stopped chelation for at least 6 months and 2 patients (22.2%) received phlebotomy.</span></a></p><p class="C-BodyText" style="margin:0in;line-height:normal"> </p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Exploratory analyses were performed to evaluate resolution of dyserythropoiesis, the fundamental pathophysiological characteristic of TDT, in the bone marrow. Bone marrow biopsies taken before treatment were consistent with a diagnosis of TDT, including a low myeloid/erythroid ratio (N=15, HGB‑207; N=3, HGB‑212), reflective of erythroid hyperplasia. For 9 patients who achieved TI and had a Month 12 bone marrow assessment, myeloid/erythroid ratios increased from a median (min, max) of 0.2 (0.1 to 0.7) at baseline to a median (min, max) of 0.83 (0.6 to 1.9) at Month 12 after Zynteglo infusion, suggesting that Zynteglo improves erythropoiesis in patients with TDT. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><a name="_Ref442134"><u><span style="font-size:11.0pt"></span></u></a></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"><u><span style="font-size:11.0pt">Overall results</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal;page-break-after:avoid"></p><p class="MsoCaption" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;line-height:normal"><span style="font-size:11.0pt">Figure </span><span style="font-size:11.0pt">1            Median total haemoglobin over time in non-β<sup>0</sup>/β<sup>0</sup> TDT patients treated with Zynteglo who have achieved transfusion independence (Studies HGB‑204, HGB‑205, HGB‑207, LTF‑303)</span></p><p class="Default" style="text-align:justify;text-justify:inter-ideograph"><span lang="EN-GB"><img height="336" id="Picture 3" src="#image1" width="576"/></span></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal;text-autospace: none"><i><span style='font-family:"Times New Roman",serif'>Bars represent interquartile ranges.</span></i></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal;text-autospace: none"><a name="_Hlk31017224"><i><span style='font-family:"Times New Roman",serif'>Total Hb represents those without any acute or chronic RBC transfusions within 60 days prior to the measurement date.</span></i></a></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><a name="_Hlk4231781"></a></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-before:always"><b><span style='font-family:"Times New Roman",serif'>Table 5              Efficacy outcomes for non‑β<sup>0</sup>/β<sup>0</sup> TDT patients treated with Zynteglo (Studies HGB‑204, HGB‑205, HGB‑207, HGB‑212, LTF‑303)</span></b></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:1.0in;text-indent:-1.0in;line-height:normal"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="border-collapse:collapse;border:none" width="591"> <thead> <tr style="height:71.3pt"> <td style="width:.9in;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:71.3pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><b><span style='font-family:"Times New Roman",serif'>HbA<sup>T87Q</sup>    at 6 months</span></b></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>(g/dL)</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>n</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>median    (min, max)</span></p> </td> <td style="width:.9in;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><b><span style='font-family:"Times New Roman",serif'>HbA<sup>T87Q    </sup>at 24 months</span></b></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>(g/dL)</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>n</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>median</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(min,    max)</span></p> </td> <td style="width:.9in;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><b><span style='font-family:"Times New Roman",serif'>Hb    at 6 months*</span></b></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>(g/dL)</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>n</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>median</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(min,    max)</span></p> </td> <td style="width:65.5pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt" valign="top" width="87"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><b><span style='font-family:"Times New Roman",serif'>Hb    at 24 months*</span></b></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>(g/dL)</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>n</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>median</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(min,    max)</span></p> </td> <td style="width:.75in;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt" valign="top" width="72"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><b><span lang="FR" style='font-family:"Times New Roman",serif'>TI**</span></b></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span lang="FR" style='font-family:"Times New Roman",serif'>n/N^    </span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span lang="FR" style='font-family:"Times New Roman",serif'>(%)</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal;text-autospace:none"><span lang="FR" style='font-family:    "Times New Roman",serif'>[95% CI]</span></p> </td> <td style="width:.9in;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><b><span lang="DA" style='font-family:"Times New Roman",serif'>WA    Hb during TI </span></b><span lang="DA" style='font-family:"Times New Roman",serif'>(g/dL)</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>n</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>median</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(min,    max)</span></p> </td> <td style="width:.9in;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><b><span style='font-family:"Times New Roman",serif'>Duration    of TI</span></b></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>(months)</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>n</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>median</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;    line-height:normal"><span style='font-family:"Times New Roman",serif'>(min,    max)</span></p> </td> </tr> </thead> <tr style="height:2.35pt"> <td colspan="7" style="width:443.5pt;border:solid windowtext 1.0pt;   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:2.35pt" valign="top" width="591"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span style='font-family:"Times New Roman",serif;color:black'>HGB-205</span></p> </td> </tr> <tr style="height:37.55pt"> <td style="width:.9in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.55pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>4</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>7.543</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(4.94,   9.59)</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.55pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>4</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>8.147</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(6.72,   10.13)</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.55pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>4</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>10.73</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(7.6,   13.4)</span></p> </td> <td style="width:65.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.55pt" valign="top" width="87"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>4</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>10.91</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(8.8,   13.6)</span></p> </td> <td style="width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.55pt" valign="top" width="72"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>3/4 </span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>(75.0%)<br/>   [19.4, 99.4]</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.55pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>3</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>11.35</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(10.5,   13.0)</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.55pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>3</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>NR </span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>(38.2+,   57.6+)</span></p> </td> </tr> <tr style="height:1.85pt"> <td colspan="7" style="width:443.5pt;border:solid windowtext 1.0pt;   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:1.85pt" valign="top" width="591"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span style='font-family:"Times New Roman",serif;color:black'>HGB-204</span></p> </td> </tr> <tr style="height:37.4pt"> <td style="width:.9in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>10</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>4.153</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(1.03,   8.52)</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>10</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>5.418</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(1.10,   9.60)</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>7</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>9.20</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(7.7,   13.3)</span></p> </td> <td style="width:65.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="87"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>8</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>10.35</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(9.1,   13.7)</span></p> </td> <td style="width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="72"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>8/10   (80.0%)</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>[44.4,   97.5]</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>8</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>10.27</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(9.3,   13.3)</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>8</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>NR </span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>(28.3+,   51.3+)</span></p> </td> </tr> <tr style="height:5.3pt"> <td colspan="7" style="width:443.5pt;border:solid windowtext 1.0pt;   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:5.3pt" valign="top" width="591"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span style='font-family:"Times New Roman",serif;color:black'>HGB-207</span></p> </td> </tr> <tr style="height:37.4pt"> <td style="width:.9in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>13</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>9.324</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(3.35,   10.60)</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>3</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>8.766</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(0.89,   11.40)</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>15</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>11.80</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(8.4,   13.3)</span></p> </td> <td style="width:65.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="87"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>2</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>12.85</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(12.5,   13.2)</span></p> </td> <td style="width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="72"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>9/10</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>(90.0%)<br/>   [55.5, 99.7]</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>9</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>12.22</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>(11.4,   12.8)</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>9</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>NR</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>(12.1+,   21.3+)</span></p> </td> </tr> <tr style="height:.2in"> <td colspan="7" style="width:443.5pt;border:solid windowtext 1.0pt;   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:.2in" width="591"> <p class="MsoNormal" style="margin-bottom:0in;line-height:normal;page-break-after:   avoid"><span style='font-family:"Times New Roman",serif;color:black'>HGB-212</span></p> </td> </tr> <tr style="height:37.4pt"> <td style="width:.9in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>3</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>10.094</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>(5.06,   10.33)</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>NA***</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>3</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>12.10</span></p> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>(8.5,   12.2)</span></p> </td> <td style="width:65.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="87"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal;text-autospace:none"><span style='font-family:"Times New Roman",serif'>NA***</span></p> </td> <td style="width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="72"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>NA***</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>NA***</span></p> </td> <td style="width:.9in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:37.4pt" valign="top" width="86"> <p align="center" class="MsoNormal" style="margin-bottom:0in;text-align:center;   line-height:normal"><span style='font-family:"Times New Roman",serif'>NA***</span></p> </td> </tr> </table><p class="MsoNormal" style="margin-bottom:0in;line-height:normal;text-autospace: none"><span style='font-family:"Times New Roman",serif;color:white'>*Patients who have not received transfusions in the prior 60 days. </span></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal;text-autospace: none"><span style='font-family:"Times New Roman",serif'>**Transfusion independence (TI): a weighted average Hb ≥9 g/dL without any RBC transfusions for a continuous period of ≥12 months at any time during the study after medicinal product infusion.</span></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal;text-autospace: none"><span style='font-family:"Times New Roman",serif'>***No patients are currently evaluable for these endpoints.  </span></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal;text-autospace: none"><span style='font-family:"Times New Roman",serif'>N^ represents the total number of patients evaluable for TI, defined as patients who have completed their parent study (i.e., 24 months of follow‑up), or achieved TI, or will not achieve TI in their parent study. </span></p><p class="Default"><span style="font-size:11.0pt">NR = Not reached. NA = Not applicable. Hb = Total Hb. WA Hb = Weighted average Hb.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Paediatric population</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The European Medicines Agency has deferred the obligation to submit the results of studies with Zynteglo in one or more subsets of the paediatric population in β‑thalassaemia (see section 4.2 for information on paediatric use).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">This medicinal product has been authorised under a so-called ‘conditional approval’ scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo is an autologous gene therapy medicinal product consisting of autologous cells that have been genetically modified <i>ex vivo</i>. The nature of Zynteglo is such that conventional studies on pharmacokinetics, absorption, distribution, metabolism, and elimination are not applicable.<a name="_Hlk500249629"></a></span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Conventional mutagenicity, carcinogenicity and reproductive and developmental toxicity studies have not been conducted.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The pharmacology, toxicology and genotoxicity of the BB305 LVV used for transduction in the manufacture of Zynteglo were evaluated <i>in vitro</i> and <i>in vivo</i>. An <i>in vitro</i> immortalisation (IVIM) assay conducted with BB305 LVV‑transduced mouse bone marrow cells (BMCs) showed minimal mutagenic potential (Fitness Score ≈ 0.1 × 10<sup>-4</sup>). Insertion site analysis (ISA) of pre-transplantation transduced mouse BMCs and human CD34<sup>+</sup> HSCs showed no enrichment for insertion in or near cancer-related genes. A pharmacology, biodistribution, toxicity and genotoxicity study was conducted in a mouse model of β‑thalassaemia. In this study, there was no evidence of toxicity, genotoxicity or oncogenesis (tumorigenicity) related to BB305 LVV integration, and no toxicity related to production of β<sup>A‑T87Q</sup>‑globin. ISA of post-transplantation BMCs demonstrated no preferred integration in the proximity of or within genes associated clinically (for gamma retroviral vectors) with either clonal dominance or leukaemia, and no evidence of clonal dominance was observed. Additional studies with human CD34<sup>+</sup> HSCs administered to immunodeficient, myeloablated mice demonstrated no toxicity, tumorigenicity or genotoxicity.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Cryostor CS5</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Sodium chloride</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Frozen: 1 year at ≤-140°C.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Once thawed: maximum 4 hours at room temperature (20°C‑25°C).</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Store in the vapour phase of liquid nitrogen at ≤-140°C until ready for thaw and administration. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Keep the infusion bag(s) in the metal cassette(s). </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Do not re-freeze after thawing.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">20 mL fluorinated ethylene propylene infusion bag(s), each packed in a transparent pouch inside a metal cassette. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Zynteglo is shipped from the manufacturing facility to the infusion centre storage facility in a cryoshipper, which may contain multiple metal cassettes intended for a single patient. Each metal cassette contains one infusion bag with Zynteglo. A patient may have multiple infusion bags. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal and other handling"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">Irradiation could lead to inactivation of the product.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Precautions to be taken before handling or administering the medicinal product</span></i></p><p class="C-BodyText" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;text-indent:-.25in;line-height:normal"><span style="font-size: 11.0pt;font-family:Symbol">·</span><span style="font-size:11.0pt">This medicinal product contains genetically modified human blood cells. Healthcare professionals handling Zynteglo should take appropriate precautions (wearing gloves, protective clothing and eye protection) to avoid potential transmission of infectious diseases.  </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Preparation for the infusion</span></i></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">Remove each metal cassette from liquid nitrogen storage and remove each infusion bag from the metal cassette.</span></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">Confirm that Zynteglo is printed on the infusion bag(s).</span></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">Confirm that patient identity matches the unique patient identification information located on the Zynteglo infusion bag(s). Do not infuse Zynteglo if the information on the patient specific‑label on the infusion bag does not match the intended patient.</span></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">Account for all infusion bags and confirm each infusion bag is within the expiry date using the accompanying Lot Information Sheet. </span></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">Each infusion bag should be inspected for any breaches of integrity before thawing and infusion. If an infusion bag is compromised, follow the local guidelines and contact bluebird bio immediately.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><i><span style="font-size:11.0pt">Thaw and administration</span></i></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;text-indent:-13.5pt;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">Thaw Zynteglo at 37°C in a water bath or dry bath. Thawing of each infusion bag takes approximately 2 to 4 minutes. Do not overthaw the medicinal product. Do not leave the medicinal product unattended and do not submerge the infusion ports if thawed in a water bath.</span></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;text-indent:-13.5pt;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">After thaw, mix the medicinal product gently by massaging the infusion bag until all of the contents are uniform. Expose the sterile port on the infusion bag by tearing off a protective wrap covering the port. </span></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;text-indent:-13.5pt;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">Access the medicinal product infusion bag and infuse per the administration site’s standard procedures for administration of cell therapy products. Do not use an in-line blood filter or an infusion pump.</span></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;text-indent:-13.5pt;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">Do not sample, alter, or irradiate the medicinal product.</span></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;text-indent:-13.5pt;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">Administer each infusion bag of Zynteglo via intravenous infusion over a period of less than 30 minutes. If more than one infusion bag is provided, administer each infusion bag completely before proceeding to thaw and infuse the next bag.</span></p><p class="C-Bullet" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in;text-indent:-13.5pt;line-height:normal"><span style="font-family:Symbol">·</span><span style="font-size:11.0pt">Infuse Zynteglo as soon as possible and no more than 4 hours after thawing. Flush all Zynteglo remaining in the infusion bag and any associated tubing with at least 50 mL of 0.9% sodium chloride solution to ensure as many cells as possible are infused into the patient.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt">Precautions to be taken for the disposal of the medicinal product</span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><u><span style="font-size:11.0pt"></span></u></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">The medicinal product contains genetically‑modified cells. Local guidelines on handling human-derived material should be followed for unused medicinal products or waste material. All material that has been in contact with Zynteglo (solid and liquid waste) should be handled and disposed of as potentially infectious waste in accordance with local guidelines on handling human-derived material. </span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span style="font-size:11.0pt">bluebird bio (Netherlands) B.V.</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Stadsplateau 7</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">WTC Utrecht</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">3521AZ Utrecht</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">The Netherlands</span></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p><p class="C-BodyText" style="margin:0in;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S) "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt;line-height:normal"><span style='font-family:"Times New Roman",serif'>EU/1/19/1367/001</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt;line-height:normal"><span style='font-family:"Times New Roman",serif'>Date of first authorisation: 29 May 2019</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-bottom:0in;line-height:normal"></p><p class="MsoNormal" style="margin-bottom:0in;line-height:normal"><span style='font-family:"Times New Roman",serif'>{DD month YYYY}</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"><span lang="EN-GB" style='font-family:"Times New Roman",serif'>Detailed information on this medicinal product is available on the website of the European Medicines Agency </span><a href="http://www.ema.europa.eu"><span lang="EN-GB" style='font-family:"Times New Roman",serif'>http://www.ema.europa.eu</span></a><span lang="EN-GB" style='font-family:"Times New Roman",serif'>&lt;, and on the website of {name of MS Agency (link)}&gt;. <br clear="all" style="page-break-before:always"/> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:27.0pt;text-indent:-27.0pt;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:27.0pt;text-indent:-27.0pt;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:27.0pt;text-indent:-27.0pt;line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:27.0pt;text-indent:-27.0pt;line-height:normal"></p><p align="center" class="MsoNormal" style="margin-top:0in;margin-right:-.1pt; margin-bottom:0in;margin-left:27.0pt;text-align:center;text-indent:-27.0pt; line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>